AI Terminal

MODULE: AI_ANALYST
Interactive Q&A, Risk Assessment, Summarization
MODULE: DATA_EXTRACT
Excel Export, XBRL Parsing, Table Digitization
MODULE: PEER_COMP
Sector Benchmarking, Sentiment Analysis
SYSTEM ACCESS LOCKED
Authenticate / Register Log In

IMCD N.V.

Earnings Release Aug 4, 2023

3853_iss_2023-08-04_487b4bfb-8cc6-4cea-a7e2-07ec160cee86.pdf

Earnings Release

Open in Viewer

Opens in native device viewer

Press release

IMCD reports EBITA of EUR 280 million in the first half of 2023

Rotterdam, The Netherlands (4 August 2023) - IMCD N.V. ("IMCD" or "Company"), a global leading distribution partner, formulator of speciality chemicals and ingredients, and solutions provider, today announces its first half year 2023 results.

HIGHLIGHTS

  • Gross profit of EUR 583 million (+2% on a constant currency basis) showed resilience of IMCD's business model
  • Operating EBITA decrease of 6% to EUR 280 million (-3% on a constant currency basis)
  • Net result decrease of 14% to EUR 153 million (-12% on a constant currency basis)
  • Free cash flow increased by 105% to EUR 241 million (first half of 2022: EUR 118 million)
  • Successful completion of acquisitions in the UK, Sweden, Israel, South Africa, Puerto Rico, Colombia and India, and agreements signed to acquire entities in Chile, Singapore and Malaysia

Piet van der Slikke, CEO: "After an exceptional performance in 2022 and despite current challenging macroeconomic conditions, IMCD showed its resilience in the first six months of the year by achieving a gross profit of EUR 583 million (+2% forex adjusted) and an operating EBITA of EUR 280 million (-3% forex adjusted). IMCD delivered a healthy cash flow of over EUR 240 million (+105%), and a strong cash conversion margin of 84%. We remain confident about our diversified business model and continue to execute our growth strategy with diligence. With thirteen acquisitions this year, of which seven acquisitions in Latin America and Asia, we further expanded our global market presence and are well-positioned to deliver future business growth."

KEY FIGURES

EUR MILLION JAN. 1 - JUNE 30, 2023 JAN. 1 - JUNE 30, 2022 CHANGE CHANGE FX ADJ. CHANGE
Revenue 2,287 2,318 (31) (1%) 1%
Gross profit 583 584 (2) 0% 2%
Gross profit as a % of revenue 25.5% 25.2% 0.3%
Operating EBITA1 280 297 (17) (6%) (3%)
Operating EBITA as a % of revenue 12.2% 12.8% (0.6%)
Conversion margin2 48.1% 50.8% (2.7%)
Net result 153 177 (24) (14%) (12%)
Free cash flow3 241 118 123 105%
Cash conversion margin4 84.4% 38.9% 45.5%
Earnings per share (weighted) 2.68 3.11 (0.43) (14%) (12%)
Cash earnings per share (weighted)5 3.28 3.68 (0.40) (11%) (9%)

Number of full time employees end of period 4,549 4,013 536 13%

1 Result from operating activities before amortisation of intangibles and non-recurring items

2 Operating EBITA in percentage of gross profit

3 Operating EBITDA excluding non-cash share-based payment expenses, less lease payments, plus/less changes in working capital, less capital expenditures

4 Free cash flow in percentage of adjusted operating EBITDA (operating EBITDA plus non-cash share-based payment costs minus lease payments)

5 Result for the year before amortisation (net of tax) divided by the weighted average number of outstanding shares

Revenue

In the first half of 2023, revenue decreased by 1% to EUR 2,287.2 million, compared with the same period of 2022. On a constant currency basis, revenue increased by 1%, consisting of an organic decline of 6% and the impact of the first-time inclusion of companies acquired in 2022 and 2023 of 7%.

Gross profit

Gross profit, defined as revenue less costs of materials and inbound logistics, was EUR 582.5 million in the first half of 2023, compared with EUR 584.2 million in the same period of 2022. On a constant currency basis, the gross profit growth was 2%, consisting of an organic decrease of 3% and the impact of the first-time inclusion of businesses acquired in 2022 and 2023 of 5%.

Gross profit as a % of revenue increased by 0.3%-point from 25.2% in the first half of 2022 to 25.5% in 2023. The gross profit margin increase is the result of changes in local market conditions, gross margin improvement initiatives, fluctuations in the product mix and currency exchange rate movements.

Operating EBITA

Operating EBITA decreased by 6% from EUR 296.7 million in the first half of 2022 to EUR 280.1 million in the same period of 2023. On a constant currency basis operating EBITA decreased by 3%. The decline in operating EBITA, on a constant currency basis, is a combination of organic decline (-8%) and the impact of the first-time inclusion of companies acquired in 2022 and 2023 (+5%).

Operating EBITA as a % of revenue decreased by 0.6%-point from 12.8% in the first half of 2022 to 12.2% in 2023.

The conversion margin, defined as operating EBITA as a percentage of gross profit, decreased by 2.7%-point from 50.8% in the first half of 2022 to 48.1% in 2023. The decrease in conversion margin is the result of higher gross profit being more than offset by the growth of the operating expenses. Organic increase of operating expenses is mainly driven by the impact of higher than usual cost inflation in most of the regions.

Cash flow and capital expenditure

In the first half of 2023, free cash flow was EUR 240.9 million compared with EUR 117.6 million in the first half of 2022 (+EUR 123.3 million).

The cash conversion margin, defined as free cash flow as a percentage of adjusted operating EBITDA (Operating EBITDA adjusted for non-cash share-based payments and lease payments), was 84.4% compared with 38.9% in the first half of 2022. The increase of the cash conversion margin in 2023 is the result of lower operating EBITDA more than offset by lower investments in net working capital.

The investment in net working capital (sum of inventories, trade and other receivables minus trade and other payables) in the first half of 2023 was EUR 40.0 million compared with EUR 179.9 million in the first half of 2022. The reduced working capital investments were primarily driven by the lower level of business activities in the first half of 2023. As at the end of June 2023, net working capital in days of revenue was 65 days (June 2022: 65 days).

Capital expenditure was EUR 4.6 million in the first half of 2023 compared with EUR 5.1 million in the same period of 2022 and mainly relates to investments in the ICT infrastructure, office improvements and technical equipment.

Net debt

As at 30 June 2023, net debt was EUR 1,268.0 million compared with EUR 1,026.9 million as of 31 December 2022.

The leverage ratio (net debt/operating EBITDA ratio including full year impact of acquisitions) as at the end of June 2023, was 2.1 times EBITDA (31 December 2022: 1.7). Calculated on the basis of the definitions used in the IMCD loan documents, the leverage ratio as at the end of June 2023 was 1.6 times EBITDA (31 December 2022: 1.3), which is well below the maximum of 4.25 as allowed under the loan documents.

The leverage development in the first half of 2023 is, among other things, influenced by a dividend payment of EUR 135.1 million in May and by considerations paid for acquired business of EUR 166.7 million.

DEVELOPMENTS BY OPERATING SEGMENT

The reporting segments are defined as follows:

  • EMEA: all operating companies in Europe, Turkey, Israel, United Arab Emirates, Saudi Arabia and Africa
  • Americas: all operating companies in the United States of America, Canada, Brazil, Puerto Rico, Chile, Argentina, Uruguay, Colombia, Ecuador, Mexico, Peru, Guatemala, Costa Rica and Dominican Republic
  • Asia Pacific: all operating companies in Australia, New Zealand, India, Bangladesh, China, Singapore, Malaysia, Indonesia, Philippines, Thailand, Vietnam, Japan and South Korea
  • Holding companies: all non-operating companies, including the head office in Rotterdam and the regional offices in Singapore and the USA

The developments by operating segment in the first half of 2023 are as follows.

EMEA

EUR MILLION JAN. 1 - JUNE 30, 2023 JAN. 1 - JUNE 30, 2022 CHANGE CHANGE FX ADJ. CHANGE
Revenue 1,009.2 1,052.3 (43.1) (4%) (1%)
Gross profit 275.3 280.0 (4.7) (2%) 1%
Gross profit as a % of revenue 27.3% 26.6% 0.7%
Operating EBITA 130.6 140.4 (9.8) (7%) (4%)
Operating EBITA as a % of revenue 12.9% 13.3% (0.4%)
Conversion margin 47.4% 50.1% (2.7%)

Revenue decreased by 4% from EUR 1,052.3 million in the first half of 2022 to EUR 1,009.2 million in 2023. On a constant currency basis, revenue decrease was 1%. Gross profit decreased by 2% to EUR 275.3 million in the first half of 2023 (+1% on a constant currency basis). Gross profit margin increased by 0.7%-point to 27.3%.

Operating EBITA decreased by 7% from EUR 140.4 million in the first half of 2022 to EUR 130.6 million in 2023. On a constant currency basis the decrease in operating EBITA was 4%. Compared with the same period in 2022, operating EBITA as a % of revenue decreased by 0.4%-point to 12.9% in the first half of 2023.

On 20 April 2023, IMCD acquired 100% of the share capital of ACM AB ("ACM"), a distributor of minerals and chemicals. Based in Sweden, ACM is mostly active within the coatings, adhesives, paper, plastics, rubber, and construction industries. With six employees, ACM generated revenues of approximately EUR 13 million in 2022.

On 1 May 2023, IMCD acquired the import and distribution business of Tagra Biotechnologies Ltd. ("Tagra Distribution Division"), a distributor and supplier of cosmetic raw materials and ingredients for the beauty and personal care industry in Israel. In 2022, Tagra Distribution Division generated revenues of approximately EUR 7 million and adds seven employees to the IMCD Israel team.

On 7 June 2023, IMCD acquired 100% of the shares of KOI Products Solutions and Engineering Ltd ("KOI Products Solutions"). KOI Products Solutions has partnerships with some of the world's leading suppliers of speciality products and predominantly serves the composite, paint, cosmetics, coatings, and ink markets. The company, based in Petach Tikva, Israel, generated revenues of approximately EUR 8 million in the financial year 2022 and adds 13 employees to the IMCD Israel team.

The first half of 2023 results include, in addition to the aforementioned acquisitions, the impact of the acquisition of Polychem (South Eastern Europe) in February 2022, Evenlode (UK and Ireland) in March 2022 and Orange Chemicals (UK) in February 2023.

On 3 July 2023, IMCD acquired 100% of the shares in CPS Chemical Oil-Tech (Pty) Ltd ("CPS Oil-Tech"), a distributor of raw materials to the petroleum, additive, grease manufacturing and other industry related segments in South Africa. With 8 employees, CPS Oil-Tech generated revenues of approximately EUR 12 million in the financial year that ended on February 28, 2022.

On 13 July 2023, IMCD acquired 90% of the shares of O&3 Limited, ("O&3"), an industry leading supplier of speciality natural ingredients to the global beauty and personal care markets. With 69 employees, across its offices and facilities in Ripon (UK), Warka (Poland) and New York (USA), O&3 generated revenues of approximately EUR 37 million in the financial year that ended on March 31, 2023.

Americas

EUR MILLION JAN. 1 - JUNE 30, 2023 JAN. 1 - JUNE 30, 2022 CHANGE CHANGE FX ADJ. CHANGE
Revenue 738.4 773.1 (34.7) (4%) (5%)
Gross profit 178.8 183.7 (4.9) (3%) (3%)
Gross profit as a % of revenue 24.2% 23.8% 0.4%
Operating EBITA 87.7 93.1 (5.4) (6%) (6%)
Operating EBITA as a % of revenue 11.9% 12.0% (0.1%)
Conversion margin 49.0% 50.7% (1.7%)

In the first half of 2023, revenue decreased by 4% compared to the same period of 2022. On a constant currency basis, revenue decrease was 5%. Gross profit decline was 3% to EUR 178.8 million in 2023, compared with EUR 183.7 million in the first half of 2022 (-3% on a constant currency basis). Gross profit margin increased by 0.4% point from 23.8% in the first half of 2022 to 24.2% in 2023.

Operating EBITA decreased by 6% from EUR 93.1 million in the first half of 2022 to EUR 87.7 million in 2023 (-6% on a constant currency basis). Operating EBITA as a % of revenue decreased by 0.1%-point to 11.9%.

On 19 May 2023, IMCD acquired 100% of the shares of Allianz Group International S.A.S. ("Allianz"). Allianz is a distributor of active pharmaceutical ingredients (API) and serves the Colombian market. Headquartered in Bogotá, Colombia, Allianz has 25 employees and generated revenues of approximately EUR 7 million in 2022.

The first half of 2023 results include, in addition to the acquisition of Allianz, the impact of the acquisitions of Polyorganic (Brazil) and Quelaris (Colombia, Costa Rica and Peru) in March 2022, and Promaplast (Mexico) in September 2022.

On 18 July 2023, IMCD signed an agreement to acquire 100% of the shares of Representaciones de Materias Primas Industriales Limitada ("MAPRIN"). MAPRIN is a raw materials distributor for the beauty and personal care industry, headquartered in Santiago, Chile. MAPRIN has 20 employees and generated revenues to its LATAM organisation of approximately EUR 8 million in 2022. The closing of the transaction is subject to customary closing conditions and is expected to take place in August 2023.

On 2 August 2023, IMCD acquired 100% of the shares of Sachs Chemical, Inc. ("Sachs"). Headquartered in San Juan, Puerto Rico, Sachs is a speciality chemicals distributor, providing customised solutions for the pharmaceutical industry. With 38 employees, Sachs generated revenues of approximately EUR 48 million in 2022.

Asia Pacific

EUR MILLION JAN. 1 - JUNE 30, 2023 JAN. 1 - JUNE 30, 2022 CHANGE CHANGE FX ADJ. CHANGE
Revenue 539.6 492.5 47.1 10% 16%
Gross profit 128.4 120.4 8.0 7% 13%
Gross profit as a % of revenue 23.8% 24.4% (0.6%)
Operating EBITA 78.8 79.1 (0.3) (0%) 5%
Operating EBITA as a % of revenue 14.6% 16.1% (1.5%)
Conversion margin 61.4% 65.7% (4.3%)

In the first half of 2023, revenue increased by 10% to EUR 539.6 million (+16% on a constant currency basis). Gross profit increased by 7% to EUR 128.4 million in the first half of 2023, compared with EUR 120.4 million in the same period in 2022 (+13% on a constant currency basis). Gross profit as a % of revenue was 23.8% in the first half of 2023, compared with 24.4% in the same period of 2022.

Operating EBITA remained relatively stable at EUR 78.8 million in the first half of 2023. On a constant currency basis operating EBITA increased by 5%. In the first half of 2023, operating EBITA as a % of revenue was 14.6% compared with 16.1% in the same period of last year.

On 20 April 2023, IMCD acquired 100% of the shares in Tradeimpex Polymers (India) Private Limited ("Tradeimpex"), a distributor of high-performance polymers and engineering plastics. With 24 employees, Tradeimpex generated revenues of approximately EUR 39 million in the financial year that ended on March 31, 2022.

On 18 May 2023, IMCD signed an agreement to acquire 100% of the shares of the speciality distribution company, Euro Chemo-Pharma Sdn Bhd ("Euro Chemo-Pharma") and its wholly owned subsidiary, Biofresh Green Sdn Bhd ("Biofresh") in Malaysia. Together with 124 employees, Euro Chemo-Pharma and Biofresh are offering a wide range of products, mainly food, pharmaceutical and personal care applications and generated revenues of approximately EUR 55 million in the financial year ended on June 30, 2022. The closing of the transaction is subject to customary closing conditions and is expected to take place in the last quarter of 2023.

On 15 June 2023, IMCD signed an agreement to acquire 100% of the shares of the speciality distribution company Brylchem Pte Ltd and the business of Chemipac Pte Ltd. in Singapore, and the business of CMS Marketing Trading Co., Ltd in Vietnam ("jointly Brylchem Group"). Brylchem Group offers a wide range of products in the coatings, construction, advanced materials, agrochemical, home care and industrial cleaning, feed and veterinary, and lubricants industries, for the Singapore and Vietnam markets. With approximately 50 employees, Brylchem Group generated revenues of approximately EUR 58 million in 2022. The closing of the transaction is subject to customary closing conditions and is expected to take place in the last quarter of 2023.

The first half of 2023 results include, in addition to the acquisition of Tradeimpex, the impact of the acquisitions of RPL Trading (Australia and New Zealand) and Syntec (China) in January 2022, Aquatech (China) in February 2022, Kuni Chemical (Japan) in September 2022, and Welex (China) and Parkash DyeChem (India) in December 2022, and Sanrise (China) in March 2023.

Holding companies

EUR MILLION JAN. 1 - JUNE 30, 2023 JAN. 1 - JUNE 30, 2022 CHANGE CHANGE FX ADJ. CHANGE
Operating EBITA (17.1) (15.9) (1.2) (8%) (7%)
Operating EBITA as a % of total revenue (0.7%) (0.7%) - %

Operating EBITA of Holding companies represents costs relating to the central head office in Rotterdam and the regional head offices in Singapore and in the USA.

Operating expenses increased by EUR 1.2 million from EUR 15.9 million in the first half of 2022 to EUR 17.1 million in 2023. Operating expenses as a percentage of the consolidated revenue was 0.7% in the first half of 2023, in line with the same period of last year. The cost increase reflects the growth of IMCD and as a consequence the need to further strengthen the support functions in both Rotterdam and the regional head offices.

OUTLOOK

IMCD operates in different, often fragmented market segments in multiple geographic regions, connecting many customers and suppliers across a very diverse product range. In general, results are impacted by macroeconomic conditions and developments in specific industries.

Results can be influenced from period to period by, among other things, the ability to maintain and expand commercial relationships, the ability to introduce new products and start new customer and supplier relationships and the timing, scope and impact of acquisitions.

IMCD's consistent strategy and resilient business model has led to successful expansion over the years and IMCD remains focused on achieving earnings growth by optimising its services and further strengthening its market positions. IMCD sees interesting opportunities to further increase its global footprint and expand its product portfolio both organically and by acquisitions.

Given the macro-economic uncertainties it is prudent not to give a near-term trading outlook.

FINANCIAL CALENDAR

10 November 2023 First nine months 2023 results
1 March 2024 Full year 2023 results
26 April 2024 First quarter 2024 results
14 May 2024 Annual General Meeting
For further information: Investor Relations
T: +31 (0)102908684
[email protected]

FURTHER INFORMATION

Today's analysts conference call and webcast will start at 10:00 am CET. A recording of the call and webcast will be made available on the IMCD website (www.imcdgroup.com).

ABOUT IMCD N.V.

IMCD N.V. based in Rotterdam, The Netherlands, is a leading global distribution partner and formulator of speciality chemicals and ingredients. IMCD is an expert solutions provider and adds sustainable value to the supply chain. Every day professionals focus on providing the best service through commercial and operational excellence. The company is mindful of the role they play in creating a better planet for all and formulates with consciousness and executes with care, to address business challenges of tomorrow, in partnership and transparency. 

In 2022, with over 4,300 employees, IMCD realised revenues of EUR 4,601 million. IMCD N.V.'s shares are traded at Euronext, Amsterdam (symbol: IMCD) and included in the Dutch ESG AEX index, as one of 25 companies within the AEX and AMX indices demonstrating best ESG practices.

For further information, please visit www.imcdgroup.com

Disclaimer forward looking statements

This press release may contain forward looking statements. These statements are based on current expectations, estimates and projections of IMCD's management and information currently available to the Company. IMCD cautions that such statements contain elements of risk and uncertainties that are difficult to predict and that could cause actual performance and position to differ materially from these statements. IMCD disclaims any obligation to update or revise any statements made in this press release to reflect subsequent events or circumstances, except as required by law.

In the annual report of IMCD N.V. the relevant risk categories and risk factors that could adversely affect the Company's business and financial performance have been described. They are deemed to be incorporated in this release.

This press release contains inside information as meant in clause 7 of the Market Abuse Regulation and was issued on 4 August 2023, 07:00 am CET.

IMCD N.V.

CONDENSED CONSOLIDATED INTERIM FINANCIAL STATEMENTS FOR THE FIRST HALF YEAR 2023

Condensed consolidated statement of financial position 11
Condensed consolidated statement of profit or loss and comprehensive income 13
Condensed consolidated statement of changes in equity 15
Condensed consolidated statement of cash flows 16
Notes to the condensed consolidated interim financial statements 17

CONDENSED CONSOLIDATED STATEMENT OF FINANCIAL POSITION

EUR 1,000
NOTE
30 JUNE 2023 31 DECEMBER 2022
Assets
Property, plant and equipment 117,401 113,327
Goodwill 1,502,408 1,386,552
Other intangible assets 608,771 554,552
Intangible assets 2,111,179 1,941,104
Equity-accounted investees 17 71
Other financial assets 6,789 7,016
Deferred tax assets 38,801 35,614
Non-current assets 2,274,187 2,097,132
Inventories 632,748 622,098
Trade and other receivables 824,610 702,275
Cash and cash equivalents 219,785 222,005
Current assets 1,677,143 1,546,378
Total assets 3,951,330 3,643,510

CONDENSED CONSOLIDATED STATEMENT OF FINANCIAL POSITION

EUR 1,000 NOTE 30 JUNE 2023 31 DECEMBER 2022
Equity
Share capital
9 9,118 9,118
Share premium 1,051,438 1,051,438
Reserves (98,295) (69,511)
Retained earnings 542,092 367,839
Unappropriated result 152,695 313,081
Total shareholders' equity 1,657,048 1,671,965
Non-controlling interests 1,417 1,451
Total equity 1,658,465 1,673,416
Liabilities
Loans and borrowings 10 777,154 912,889
Employee benefits 18,302 22,254
Provisions 15,536 13,814
Deferred tax liabilities 147,003 130,819
Total non-current liabilities 957,995 1,079,776
Loans and borrowings 10 40,000 40,000
Other short term financial liabilities 10 670,602 296,042
Trade payables 467,394 389,021
Other payables 156,874 165,255
Total current liabilities 1,334,870 890,318
Total liabilities 2,292,865 1,970,094
Total equity and liabilities 3,951,330 3,643,510

CONDENSED CONSOLIDATED STATEMENT OF PROFIT OR LOSS AND COMPREHENSIVE INCOME

EUR 1,000 NOTE JAN. 1 - JUNE 30, 2023 JAN. 1 - JUNE 30, 2022
Revenue 6 2,287,154 2,317,927
Other income 10,986 11,021
Operating income 2,298,140 2,328,948
Cost of materials and inbound logistics (1,704,643) (1,733,760)
Cost of warehousing, outbound logistics and other services (61,834) (67,753)
Wages and salaries (142,494) (133,195)
Social security and other charges (38,884) (36,279)
Depreciation of property, plant and equipment (15,469) (14,827)
Amortisation of intangible assets (38,381) (36,904)
Other operating expenses (57,415) (53,376)
Operating expenses (2,059,120) (2,076,094)
Result from operating activities 239,020 252,854
Finance income 1,724 993
Finance costs (27,543) (8,792)
Net finance costs 7 (25,819) (7,799)
Share of profit of equity-accounted investees, net of tax (54) (12)
Result before income tax 213,147 245,043
Income tax expense (60,486) (68,023)
Result for the year 152,661 177,020
Result for the year attributable to the shareholders of the Company 152,695 177,051
Result for the year attributable to non-controlling interest (34) (31)
Result for the year 152,661 177,020
Gross profit1 582,511 584,167
Gross profit as a % of revenue 25.5% 25.2%
Operating EBITA2 4 280,090 296,714
Operating EBITA as a % of revenue 12.2% 12.8%

1 Revenue minus cost of materials and inbound logistics

2 Result from operating activities before amortisation of intangibles and non-recurring items

CONDENSED CONSOLIDATED STATEMENT OF PROFIT OR LOSS AND COMPREHENSIVE INCOME (CONTINUED)

EUR 1,000 JAN. 1 - JUNE 30, 2023 JAN. 1 - JUNE 30, 2022
Result for the year 152,661 177,020
Defined benefit plan actuarial gains/(losses) (767) 1,614
Related tax 193 (443)
Items that will never be reclassified to profit or loss (574) 1,171
Foreign currency translation differences re foreign operations (31,466) 68,626
Related tax 825 (857)
Items that are or may be reclassified to profit or loss (30,641) 67,769
Other comprehensive income for the period, net of income tax (31,215) 68,940
Total comprehensive income for the period 121,446 245,960
Total comprehensive income attributable to:
Shareholders of the Company 121,446 245,837
Non-controlling interests - 123
Total comprehensive income for the period 121,446 245,960
Weighted average number of shares 56,916,267 56,947,309
Basic earnings per share 2.68 3.11
Diluted earnings per share 2.72 3.15

CONDENSED CONSOLIDATED STATEMENT OF CHANGES IN EQUITY

UNAPPRO TOTAL NON
SHARE SHARE TRANSLATION HEDGING RESERVE OWN OTHER RETAINED PRIATED SHAREHOLDERS' CONTROLLING
EUR 1,000 NOTE CAPITAL PREMIUM RESERVE RESERVE SHARES RESERVES EARNINGS RESULT EQUITY INTEREST TOTAL EQUITY
Balance as at 1 January 2023 9,118 1,051,438 (58,761) (210) (13,580) 3,041 367,839 313,081 1,671,965 1,451 1,673,416
Appropriation of prior year's result - - - - - - 178,020 (178,020) - - -
9,118 1,051,438 (58,761) (210) (13,580) 3,041 545,858 135,061 1,671,965 1,451 1,673,416
Result for the year - - - - - - - 152,695 152,695 (34) 152,661
Total other comprehensive income - - (30,641) - - (574) - - (31,215) - (31,215)
Total comprehensive income for the
year - - (30,641) - - (574) - 152,695 121,480 (34) 121,446
Cash dividend - - - - - - - (135,061) (135,061) - (135,061)
Share based payments - - - - - (1,805) (4,160) - (5,965) - (5,965)
Purchase and transfer own shares - - - - 4,235 - 394 - 4,629 - 4,629
Total contributions by and distributions
to owners of the Company - - - - 4,235 (1,805) (3,766) (135,061) (136,397) - (136,397)
Balance as at 30 June 2023 9 9,118 1,051,438 (89,402) (210) (9,345) 662 542,092 152,695 1,657,048 1,417 1,658,465
UNAPPRO TOTAL NON
EUR 1,000 SHARE
CAPITAL
SHARE
PREMIUM
TRANSLATION
RESERVE
HEDGING
RESERVE
RESERVE OWN
SHARES
OTHER
RESERVES
RETAINED
EARNINGS
PRIATED
RESULT
SHAREHOLDERS'
EQUITY
CONTROLLING
INTEREST
TOTAL EQUITY
Balance as at 31 December 2021 9,118 1,051,438 (58,285) (100) (2,172) (3,337) 255,888 207,276 1,459,825 1,529 1,461,354
Adjustment for IAS 29 - Turkey - - - - - - 4,953 - 4,953 - 4,953
Balance as at 1 January 2022 9,118 1,051,438 (58,285) (100) (2,172) (3,337) 260,841 207,276 1,464,778 1,529 1,466,307
Appropriation of prior year's result - - - - - - 115,047 (115,047) - - -
9,118 1,051,438 (58,285) (100) (2,172) (3,337) 375,887 92,229 1,464,778 1,529 1,466,307
Result for the year - - - - - - - 177,051 177,051 (31) 177,020
Total other comprehensive income - - 67,646 - - 1,171 - - 68,817 123 68,940
Total comprehensive income for the
year - - 67,646 - - 1,171 - 177,051 245,868 92 245,960
Cash dividend - - - - - - - (92,229) (92,229) - (92,229)
Share based payments - - - - - (1,674) (7,789) - (9,463) - (9,463)
Purchase and transfer own shares - - - - (5,517) - 4,681 - (836) - (836)
Total contributions by and distributions
to owners of the Company
- - - - (5,517) (1,674) (3,108) (92,229) (102,528) - (102,528)
Balance as at 30 June 2022 9,118 1,051,438 9,361 (100) (7,689) (3,840) 372,779 177,051 1,608,118 1,621 1,609,739

CONDENSED CONSOLIDATED STATEMENT OF CASH FLOWS

EUR 1,000 NOTE JAN. 1 - JUNE 30, 2023 JAN. 1 - JUNE 30, 2022
Cash flows from operating activities
Result for the period 152,661 177,020
Adjustments for:

Depreciation of property, plant and equipment
15,469 14,827

Amortisation of intangible assets
38,381 36,904

Net finance costs excluding currency exchange results
22,509 12,005

Currency exchange results
3,310 (4,206)

Cost of share based payments
2,451 2,538

Share of profit of equity-accounted investees, net of tax
54 12

Income tax expense
60,486 68,023
295,321 307,123
Change in:

Inventories
5,779 (81,695)

Trade and other receivables
(101,841) (184,867)

Trade and other payables
56,105 86,650

Provisions and employee benefits
(3,615) (1,547)
Cash generated from operating activities 251,750 125,665
Interest paid (23,498) (14,026)
Income tax paid (56,351) (57,079)
Net cash from operating activities 171,900 54,559
Cash flows from investing activities
Acquisition of subsidiary, net of cash acquired and divestures 5 (166,680) (92,575)
Acquisition of intangible assets (8,616) (3,448)
Acquisition of property, plant and equipment (4,570) (5,077)
Acquisition of other financial assets 383 152
Net cash used in investing activities (179,482) (100,947)
Cash flows from financing activities
Dividends paid 9 (135,061) (92,229)
Purchase of and transfer own shares 0 (7,369)
Share based payments (3,787) (5,465)
Payment of transaction costs related to loans and borrowings (1,920) (2,346)
Movements in bank loans and other short term financial liabilities 10, 11 19,338 32,992
Proceeds from issue of current and non-current loans and borrowings 240,000 504,161
Repayment of loans and borrowings 10, 11 (94,916) (375,174)
Redemption of lease liabilties (11,894) (10,746)
Net cash from financing activities 11,761 43,824
Net increase in cash and cash equivalents 4,179 (2,564)
Cash and cash equivalents as at 1 January 222,005 177,879
Effect of exchange rate fluctuations (6,399) 7,380
Cash and cash equivalents as at 30 June 219,785 182,695

NOTES TO THE CONDENSED CONSOLIDATED INTERIM FINANCIAL STATEMENTS

1. Reporting entity

IMCD N.V. (the 'Company') is a public limited company domiciled in The Netherlands and registered in The Netherlands Chamber of Commerce Commercial register under number 21740070. The address of the Company's registered office is Wilhelminaplein 32, Rotterdam. The condensed consolidated interim financial statements of the Company as at and for the first half year ended 30 June 2023, comprise the Company and its subsidiaries (together referred to as the 'Group' and individually as 'Group entities'). The Company is acting as the parent company of the IMCD Group, a group of companies leading in sales, marketing and distribution of speciality chemicals, pharmaceutical and food ingredients. The Group has offices in Europe, Africa, North and Latin America and Asia Pacific.

2. Basis of preparation

Statement of compliance

The condensed consolidated interim financial statements have been prepared in accordance with IAS 34 Interim Financial Reporting. They do not include all the information required for a complete set of IFRS financial statements and should be read in conjunction with the consolidated financial statements of IMCD as at and for the year ended 31 December 2022. However, selected explanatory notes are included to explain events and transactions that are significant to an understanding of the changes in the Group's financial position and performance since the last annual consolidated financial statements as at and for the year ended 31 December 2022.

The condensed consolidated interim financial statements were prepared by the Management Board and were authorised for issue by the Supervisory Board on 3 August 2023.

Functional and presentation currency

The condensed consolidated interim financial statements are presented in Euro, which is the Company's functional currency. All financial information presented in Euro has been rounded to the nearest thousand, unless mentioned differently.

Use of estimates and judgements

In preparing the condensed consolidated interim financial statements, Management makes judgements, estimates and assumptions that affect the application of accounting policies and the reported amounts of assets and liabilities, income and expense. Actual results may differ from these estimates.

The significant judgements made by Management in applying the Group's accounting policies and the key sources of estimation uncertainty are the same as those applied to the consolidated financial statements as at and for the year ended 31 December 2022.

3. Changes in accounting policies

The accounting policies applied in these interim financial statements are the same as those applied in the Group's consolidated financial statements as at and for the year ended 31 December 2022.

A number of new and amended standards are effective from 1 January 2023 but do not have a material effect on the Company's condensed consolidated financial statements. The Company has not early-adopted any standard, interpretation or amendment that has been issued but is not yet effective and endorsed.

4. Operating segments

In presenting information on the basis of operating segments, segment revenue is based on the geographical location of customers. Segment assets are based on the geographical location of the assets with the exception of assets related to holding companies, which are presented in a separate reporting unit.

The reporting segments used are defined as follows:

  • EMEA: all operating companies in Europe, Turkey, Israel, United Arab Emirates, Saudi Arabia and Africa
  • Americas: all operating companies in the United States of America, Canada, Brazil, Puerto Rico, Chile, Argentina, Uruguay, Colombia, Ecuador, Mexico, Peru, Guatemala, Costa Rica and Dominican Republic
  • Asia Pacific: all operating companies in Australia, New Zealand, India, Bangladesh, China, Singapore, Malaysia, Indonesia, Philippines, Thailand, Vietnam, Japan and South Korea
  • Holding companies: all non-operating companies, including the head office in Rotterdam and the regional offices in Singapore and in the USA.
EMEA
EUR 1,000 JAN. 1 - JUNE 30, 2023 JAN. 1 - JUNE 30, 2022
Revenue 1,009,167 1,052,307
Gross profit 275,340 280,019
Operating EBITA 130,647 140,413
Result from operating activities 119,770 122,768
Total Assets 1,149,764 1,208,289
Total Liabilities 399,692 426,969

Americas

EUR 1,000 JAN. 1 - JUNE 30, 2023 JAN. 1 - JUNE 30, 2022
Revenue 738,354 773,131
Gross profit 178,810 183,734
Operating EBITA 87,691 93,084
Result from operating activities 78,987 83,941
Total Assets 805,638 819,324
Total Liabilities 252,745 269,168

Asia Pacific

EUR 1,000 JAN. 1 - JUNE 30, 2023 JAN. 1 - JUNE 30, 2022
Revenue 539,632 492,489
Gross profit 128,361 120,414
Operating EBITA 78,843 79,114
Result from operating activities 61,233 62,339
Total Assets 1,575,138 1,364,929
Total Liabilities 559,546 512,035

Holding Companies

EUR 1,000 JAN. 1 - JUNE 30, 2023 JAN. 1 - JUNE 30, 2022
Operating EBITA (17,091) (15,897)
Result from operating activities (20,970) (16,194)
Total Assets 420,789 376,051
Total Liabilities 1,080,882 952,379

Results from operating activities

Operating EBITA is defined as the sum of the result from operating activities, amortisation of intangible assets and non-recurring items. Non-recurring items include costs related to corporate restructuring and reorganisations, cost related to realised and non-realised acquisitions and other non-recurring income and expenses.

EUR 1,000 JAN. 1 - JUNE 30, 2023 JAN. 1 - JUNE 30, 2022
Result from operating activities 239,020 252,854
Amortisation of intangible assets 38,381 36,904
Non-recurring items in result from operating activities 2,690 6,956
Operating EBITA 280,090 296,714

The non-recurring expenses in 2023 and 2022 relate to acquisitions and divestment of businesses and one-off adjustments to the organisation. The non-recurring expenses in 2022 include the estimated financial impact of the winding down of the operations in Russia.

5. Business combinations

On 28 February 2023, IMCD acquired 100% of the shares in Orange Chemicals Ltd ("Orange Chemicals"), a distributor of performance chemicals throughout the UK and Ireland. Orange Chemicals, headquartered in Winchester, generated revenues of approximately EUR 30 million in the financial year 2022 and adds seven employees to the IMCD UK team.

On 15 March 2023, IMCD completed the acquisition of Shanghai Sanrise Industries & Development Co., Ltd. ("Sanrise"), one of the leading distributors in the personal care markets in China. Sanrise offers a wide range of personal care and industrial solutions with a key focus on personal care applications. With approximately 60 employees, Sanrise generated revenues of approximately EUR 90 million in 2021. The transaction will take place in two tranches, with first 70% of Sanrise's share capital acquired in March 2023, and the remaining 30% to be acquired in 2025.

On 20 April 2023, IMCD acquired 100% of the shares in Tradeimpex Polymers (India) Private Limited ("Tradeimpex"), a distributor of high-performance polymers and engineering plastics. With 24 employees, Tradeimpex generated revenues of approximately EUR 39 million in the financial year that ended on March 31, 2022.

On 20 April 2023, IMCD acquired 100% of the share capital of ACM AB ("ACM"), a distributor of minerals and chemicals. Based in Sweden, ACM is mostly active within the coatings, adhesives, paper, plastics, rubber, and construction industries. With six employees ACM generated revenues of approximately EUR 13 million in 2022.

On 1 May 2023, IMCD acquired the import and distribution business of Tagra Biotechnologies Ltd. ("Tagra Distribution Division"), a distributor and supplier of cosmetic raw materials and ingredients for the beauty and personal care industry in Israel. In 2022, Tagra Distribution Division generated revenues of approximately EUR 7 million and adds seven employees to the IMCD Israel team.

On 19 May 2023, IMCD acquired 100% of the shares of Allianz Group International S.A.S. ("Allianz"). Allianz is a distributor of active pharmaceutical ingredients (API) and serves the Colombian market. Headquartered in Bogotá, Colombia, Allianz has 25 employees and generated revenues of approximately EUR 7 million in 2022.

On 7 june 2023, IMCD acquired 100% of the shares of KOI Products Solutions and Engineering Ltd ("KOI Products Solutions"). KOI Products Solutions has partnerships with some of the world's leading suppliers of speciality products and predominantly serves the composite, paint, cosmetics, coatings, and ink markets. The company, based in Petach Tikva, Israel, generated revenues of approximately EUR 8 million in the financial year 2022, and adds 13 employees to the IMCD Israel team.

In addition to the aforementiond closed transactions, IMCD signed two agreements in the first half of 2023.

On 18 May 2023, IMCD signed an agreement to acquire 100% of the shares of the speciality distribution company, Euro Chemo-Pharma Sdn Bhd ("Euro Chemo-Pharma") and its wholly owned subsidiary, Biofresh Green Sdn Bhd ("Biofresh"), Together with 124 employees, Euro Chemo-Pharma and Biofresh are offering a wide range of products, mainly food, pharmaceutical and personal care applications and generated revenues of approximately EUR 55 million in the financial year ended on June 30, 2022. The closing of the transaction is subject to customary closing conditions and is expected to take place in the last quarter of 2023.

On 15 June 2023, IMCD signed an agreement to acquire 100% of the shares of the speciality distribution company Brylchem Pte Ltd and the business of Chemipac Pte Ltd. in Singapore, and the business of CMS Marketing Trading Co., Ltd in Vietnam ("jointly Brylchem Group"). Brylchem Group offers a wide range of products in the coatings, construction, advanced materials, agrochemical, home care and industrial cleaning, feed and veterinary, and lubricants industries, for the Singapore and Vietnam markets. With approximately 50 employees, Brylchem Group generated revenues of approximately EUR 58 million in 2022. The closing of the transaction is subject to customary closing conditions and is expected to take place in the last quarter of 2023.

After 30 June 2023 and before publication of the condensed financial statements for the first half of 2023, IMCD closed three acquisition transactions and signed an agreement.

On 3 July 2023, IMCD acquired 100% of the shares in CPS Chemical Oil-Tech (Pty) Ltd ("CPS Oil-Tech"), a distributor of raw materials to the petroleum, additive, grease manufacturing and other industry related segments in South Africa. With 8 employees, CPS Oil-Tech generated revenues of approximately EUR 12 million in the financial year that ended on February 28, 2022.

On 13 July 2023, IMCD acquired 90% of the shares of O&3 Limited, ("O&3"), an industry leading supplier of speciality natural ingredients to the global beauty and personal care markets. With 69 employees, across its offices and facilities

in Ripon (UK), Warka (Poland) and New York (USA), O&3 generated revenue of approximately EUR 37 million in the financial year that ended on March 31, 2023.

On 18 July 2023, IMCD signed an agreement to acquire 100% of the shares of Representaciones de Materias Primas Industriales Limitada ("MAPRIN"). MAPRIN is a raw materials distributor for the beauty and personal care industry, headquartered in Santiago, Chile. MAPRIN has 20 employees and generated revenues to its LATAM organisation of approximately EUR 8 million in 2022. The closing of the transaction is subject to customary closing conditions and is expected to take place in August 2023.

On 2 August 2023, IMCD acquired 100% of the shares of Sachs Chemical ("Sachs"). Headquartered in San Juan, Puerto Rico, Sachs is a speciality chemicals distributor, providing customised solutions for the pharmaceutical industry. With 38 employees, Sachs generated revenues of approximately EUR 48 million in 2022.

The seven transactions closed in the first half of 2023, added EUR 35.5 million of revenue and EUR 1.3 million of result for the year to the Group's results in 2023. If the acquisitions had occurred on 1 January 2023, management estimates that the consolidated revenue would have been EUR 2,326.0 million and the consolidated net profit would have been EUR 154.4 million in the first half of 2023. In determining these amounts, management has assumed that the fair value adjustments, determined provisionally, that arose on the date of acquisition would have been the same if the acquisition had occurred on 1 January 2023.

Identifiable assets recognised and liabilities assumed

The recognised amounts of assets acquired and liabilities assumed on the basis of provisional purchase price allocation at the acquisition dates of the acquisitions completed in the first half of 2023, are as follows:

EUR 1,000 TOTAL
Property, plant and equipment 471
Intangible assets 93,909
Deferred tax assets 1,591
Other financial assets 713
Inventories 27,461
Trade and other receivables 31,608
Cash and cash equivalents 13,006
Loans and borrowings (3,203)
Other short term financial liabilities (11,200)
Employee benefits and other provisions (1,728)
Deferred tax liabilities (22,667)
Trade and other payables (20,120)
Total net identifiable assets 109,841

Goodwill

The goodwill recognised as a result of the acquisitions is as follows:

EUR 1,000 TOTAL
Total consideration, including deferred and contingent considerations
Less: Fair value of identifiable net assets
238,619
109,841
Goodwill 128,779

The goodwill is mainly attributable to the skills and technical talent of the work force, the international network and the synergies expected to be achieved from integration of acquired companies into the Group's existing distribution business.

6. Revenue

The Group generates revenue primarily from the sale and distribution of speciality chemicals and ingredients. Other sources of revenue include revenue from commission where the Group acts as agent in the sale and distribution of speciality chemicals and ingredients.

EUR 1,000 JAN. 1 - JUNE 30, 2023 JAN. 1 - JUNE 30, 2022
Sales of goods 2,280,799 2,310,545
Commissions 6,355 7,382
Total revenue 2,287,154 2,317,927

In the following tables, revenue from contracts with customers is disaggregated by primary geographical market and their market segments, being Life Science and Industrial.

Geographical Market

The breakdown of revenue by geographical market is as follows:

EUR 1,000 JAN. 1 - JUNE 30, 2023 JAN. 1 - JUNE 30, 2022
Netherlands 38,591 46,107
Rest of EMEA 970,577 1,006,200
EMEA 1,009,167 1,052,307
North America 521,461 580,721
Latin America 216,893 192,410
Americas 738,354 773,131
Asia-Pacific 539,632 492,489
Total revenue 2,287,154 2,317,927

Market segments

IMCD's business model is based on long lasting relationships with suppliers of speciality chemicals and ingredients. In order to provide more insight into the market segments served, IMCD breaks down the sales into the market segments Life Science and Industrial.

Life Science consists of the following lines of business: Pharmaceuticals, Beauty & Personal Care, Food & Nutrition, and Home Care and I&I. In general, the lines of business within Life Science historically have been less sensitive to economic fluctuations. Furthermore, the Life Science segment generally shows lower order volumes and higher margins than the Industrial market segment.

The Industrial segment contains the lines of business of Coatings & Construction, Advanced Materials, Lubricants & Energy, and Industrial Solutions. This segment has a more cyclical nature as the performance is dependent on, amongst other things, the developments of the housing and real estate, automotive and oil & gas markets.

The breakdown of sales of goods per market segment is as follows:

EUR 1,000 JAN. 1 - JUNE 30, 2023 JAN. 1 - JUNE 30, 2022
Life Science 1,188,061 1,071,157
Industrial 1,092,738 1,239,388
Total sales of goods 2,280,799 2,310,545

7. Net finance costs

The net finance costs in the first half of 2023 consist of the following items:

EUR 1,000 JAN. 1 - JUNE 30, 2023 JAN. 1 - JUNE 30, 2022
Interest income on loans and receivables 1,724 993
Interest expenses on financial liabilities (17,775) (9,697)
Changes in deferred considerations (3,851) (1,457)
Amortisation of finance costs (1,023) (388)
Interest expenses related to employee benefits (125) (205)
Interest expenses on lease liabilities (1,459) (1,251)
Currency exchange results (3,310) 4,206
Net finance costs recognised in profit or loss (25,819) (7,799)

In the first half of 2023, net finance costs were EUR 25.8 million compared with EUR 7.8 million in the same period of 2022. The increase in interest expenses on financial liabilities mainly relates to additional credit facilities drawn, and to the increases in EURIBOR and term SOFR, applicable to the revolving and other short term bank facilities. In addition, foreign currency rate results and changes in deferred considerations had a negative impact of EUR 9.9 million in the first six months of 2023, compared to the same period in 2022.

8. Seasonality of operations

The Group is not strongly subject to seasonal fluctuations throughout the year except for a slight decrease of sales during the normal holiday seasons in the different regions.

9. Equity

Following the decision about the appropriation of the financial result 2022 by the Annual General Meeting of April 26, 2023, the Company distributed a dividend in cash of EUR 135.1 million (EUR 2.37 per share). In 2022, the Company distributed a dividend in cash of EUR 92.2 million (EUR 1.62 per share).

10. Loans and borrowings

As at 30 June 2023, net debt was EUR 1,268.0 million (31 December 2022: EUR 1,026.9 million).

On 13 February 2023, IMCD completed the refinancing of its multi-currency revolving credit facility. The new facility, with a maturity data of 13 February 2028, amounts to EUR 600 million and can be drawn in EUR and USD as well as, to an agreed sublimit, in AUD and GBP. The credit revolving facility has an interest margin dependent on external credit ratings. For the new revolving credit facility a maximum leverage of 3.75 times EBITDA (with a spike period maximum of 4.25), tested semi-annually is applicable.

As at the end of June 2023, the leverage ratio (net debt/operating EBITDA ratio including full year impact of acquisitions) was 2.1 times EBITDA (31 December 2022: 1.7).

Two leverage covenants are applicable to the Group:

  • For the Schuldscheindarlehen of EUR 40 million, a maximum leverage of 3.5 times EBITDA applies (with a spike period maximum of 4.0), tested annually.
  • For the revolving credit facilities of EUR 600 million, a maximum leverage of 3.75 times EBITDA applies (with a spike period maximum of 4.25), tested semi-annually.

The actual leverage as at 30 June 2023, calculated on the basis of the definitions used in the IMCD loan documentation, was 1.6 times EBITDA (31 December 2022: 1.3), which is well below the maximum of 4.25 as allowed under the loan documentation.

11. Financial instruments

Accounting classifications and fair values

The following table shows the carrying amounts and fair values of financial assets and financial liabilities, including their levels in the fair value hierarchy. It does not include fair value information for financial assets and financial liabilities not measured at fair value if the carrying amount is a reasonable approximation of fair value

30 JUNE 2023 CARRYING AMOUNT FAIR VALUE
EUR 1,000 NOTE FINANCIAL ASSETS AT FAIR
VALUE THROUGH PROFIT OR
LOSS
AMORTISED COST FINANCIAL LIABILITIES AT FAIR
VALUE THROUGH PROFIT OR
LOSS
OTHER FINANCIAL
LIABILITIES
TOTAL LEVEL 1 LEVEL 2 LEVEL 3 TOTAL
Forward exchange contracts
used for hedging
693 - - - 693 - 693 - 693
Forward exchange contracts
used for hedging
- - 319 - 319 - 319 - 319
Contingent consideration 11 - - 333,015 - 333,015 - - 333,015 333,015
31 DECEMBER 2022 CARRYING AMOUNT FAIR VALUE
EUR 1,000 NOTE FINANCIAL ASSETS AT FAIR
VALUE THROUGH PROFIT OR
LOSS
AMORTISED COST FINANCIAL LIABILITIES AT FAIR
VALUE THROUGH PROFIT OR
LOSS
OTHER FINANCIAL
LIABILITIES
TOTAL LEVEL 1 LEVEL 2 LEVEL 3 TOTAL
Forward exchange contracts
used for hedging
180 - - - 180 - 180 - 180
Forward exchange contracts
used for hedging
- - 1,030 - 1,030 - 1,030 - 1,030
Contingent consideration 11 - - 273,610 - 273,610 - - 273,610 273,610

Measurement of fair values

The following tables show the valuation techniques used in measuring Level 2 and Level 3 fair values, as well as the significant unobservable inputs used.

Financial instruments measured at fair value

Type Valuation technique Significant
unobservable
inputs
Inter-relationship between significant
unobservable inputs and fair value
measurement
Contingent
consideration
The valuation model considers the present
Discounted cash flows:
valueofexpectedpayment,discountedusingarisk-adjusteddiscount
rate.Theexpectedpaymentisdeterminedbyconsideringthepossible
scenarios of forecast EBITDA, the amount to be paid under each
scenario and the probability of each scenario.

Forecast
EBITDA margin

Risk-adjusted
discount rate
The estimated fair value would
increase/(decrease) if:

the EBITDA margins were higher/
(lower); or

the risk-adjusted discount rates
were lower/(higher).
Forward exchange
contracts and
interest rate swaps
The fair values are based on broker
Market comparison technique:
quotes. Similar contracts are traded in an active market and the
quotes reflect the actual transactions in similar instruments.
Not applicable Not applicable

Financial instruments not measured at fair value

Type Valuation technique Significant unobservable inputs
Financial assets 1 Discounted cash flows Not applicable
Financial liabilities 2 Discounted cash flows Not applicable

1 Financial assets include trade and other receivables and cash and cash equivalents.

2 Financial liabilities include syndicated senior bank loans, other loans and borrowings, other short term financial liabilities, trade payables and other payables.

Level 3 fair values

The following table shows the reconciliation from the opening balances to the closing balances for level 3 values.

Contingent consideration

EUR 1,000 CONTINGENT
CONSIDERATION
Balance as at 1 January 2023 273,610
Assumed in a business combination 71,629
Paid contingent consideration (9,863)
Result included in profit or loss 3,851
Effect of movement in exchange rates (6,212)
Balance as at 30 June 2023 333,015

12. Related parties

The Group has related party relationships with its shareholders, subsidiaries, associates, Management Board, Supervisory Board and post-employment benefit plans. The financial transactions between the Company and its subsidiaries comprise financing related transactions and operational transactions in the normal course of business and are eliminated in the consolidated financial statements. The related party transactions in the first half of 2023 do not substantially deviate from the transactions as reflected in the financial statements as at and for the year ended 31 December 2022.

13. Subsequent events

On 3 July 2023, IMCD acquired 100% of the shares in CPS Chemical Oil-Tech (Pty) Ltd ("CPS Oil-Tech"), a distributor of raw materials to the petroleum, additive, grease manufacturing and other industry related segments in South Africa. With 8 employees, CPS Oil-Tech generated revenues of approximately EUR 12 million in the financial year that ended on February 28, 2022.

On 13 July 2023, IMCD acquired 90% of the shares of O&3 Limited, an industry leading supplier of speciality natural ingredients to the global beauty and personal care markets. With 69 employees, across its offices and facilities in Ripon (UK), Warka (Poland) and New York (USA), O&3 generated revenue of approximately EUR 37 million in the financial year that ended on March 31, 2023.

On 18 July 2023, IMCD signed an agreement to acquire 100% of the shares of Representaciones de Materias Primas Industriales Limitada ("MAPRIN"), a raw materials distributor for the beauty and personal care industry, headquartered in Santiago, Chile. MAPRIN has 20 employees and generated revenues to its LATAM organisation of approximately EUR 8 million in 2022. The closing of the transaction is subject to customary closing conditions and is expected to take place in August 2023.

On 2 August 2023, IMCD acquired 100% of the shares of Sachs Chemical, Inc. ("Sachs"). Headquartered in San Juan, Puerto Rico, Sachs Chemical, Inc. is a speciality chemicals distributor, providing customised solutions for the pharmaceutical industry. With 38 employees, Sachs generated revenues of approximately EUR 48 million in 2022.

14. Auditor's review

The consolidated interim financial statements for the first half year of 2023 have not been audited or reviewed by the external auditor.

15. Responsibility statement

The Management Board of IMCD N.V. hereby declares that, to the best of its knowledge, the Interim Consolidated Financial information for the first half year of 2023, as prepared in accordance with IAS 34 Interim Financial Reporting, gives a true and fair view of the assets, liabilities, financial position and the profit or loss of IMCD N.V. and its jointly consolidated companies included in the consolidation as a whole, and that the semi-annual report gives a fair view of the information required in accordance with Section 5:25d subsection 8 and 9 of the Dutch Financial Supervision Act (Wet op het financieel toezicht).

Rotterdam, 3 August 2023

Management Board:

P.C.J. van der Slikke, CEO

H.J.J. Kooijmans, CFO

M.C. Jordan, COO

Talk to a Data Expert

Have a question? We'll get back to you promptly.